Outsourcing kinase and phosphatase profiling is one of the highest-impact decisions your drug discovery program will make. The right compound profiling partner accelerates your compound selection timelines. The wrong one introduces data gaps that delay go/no-go decisions by weeks or months.
This guide walks you through every factor that matters when evaluating an outsourced profiling partner, from assay technology and kinetic data depth to turnaround commitments and operational fit. AssayQuant Technologies delivers real-time kinetic profiling through its KinSight services, and we will reference that approach where it clarifies what to look for in a CRO partner.
By the end, you will have a structured framework for comparing profiling vendors on the criteria that directly affect your project timeline and data confidence.
Building in-house kinome profiling capabilities requires capital investment in instrumentation, validated reagent libraries, and specialized enzymological expertise. For many drug discovery teams, particularly at biotech and mid-size pharma organizations, that investment diverts resources from the core research mission.
Outsourcing to a dedicated profiling partner gives you access to validated panels covering hundreds of kinase targets without the overhead of maintaining those assays internally. The critical question is not whether to outsource, but how to identify a partner whose data quality, kinetic depth, and turnaround match your program's pace.
A 2026 study in the Journal of Medicinal Chemistry compared cell-free selectivity profiling with in-cell target engagement for ten kinase inhibitors and found that the two approaches can diverge enough to change which compounds get prioritized. That is a strong argument for knowing exactly how, and under what conditions, your profiling data were generated.
Assay technology is the single most consequential differentiator among profiling CROs. The method your partner uses determines what your data can and cannot tell you about your compounds.
Binding assays measure whether a compound occupies a kinase's ATP pocket. Occupancy alone does not confirm functional inhibition. Activity-based assays measure catalytic output directly, giving you rate-based percent inhibition values grounded in actual enzyme behavior.
When you are making go/no-go decisions on a compound series, you need to know whether inhibition is functional, not just whether binding occurred. Ask every prospective partner which assay format they run and what biological question their readout answers.
Traditional profiling relies on a single measurement taken at a fixed time after reaction initiation. That approach assumes linear reaction kinetics throughout the incubation period. Enzyme instability, substrate depletion, and time-dependent inhibition (TDI) all create non-linear kinetics that a single read misrepresents.
A kinome profiling partner that generates a full progress curve in every well captures true initial rates, flags TDI signals, and distinguishes between competitive, slow-binding, and irreversible inhibitors from a single experiment. That kinetic resolution is the difference between a selectivity rank and a mechanistic selectivity map.
Many profiling platforms run assays at a fixed ATP concentration, often 10 µM. That concentration sits well below physiological levels and systematically overestimates inhibitor potency for ATP-competitive compounds.
Ask your prospective partner whether they offer profiling at ATP Km (for maximal potency insight) and at 1 mM ATP (for physiological relevance). Running at both conditions gives you a clearer picture of how your compound behaves in a cellular environment.
Every target in AssayQuant's KinSight kinase and phosphatase panels is available at ATP Km, 1 mM ATP, or a custom concentration.
Panel size gets outsized attention in CRO evaluation. A panel of 400 kinases and a panel of 500 kinases may look different on paper, but the real question is whether the targets relevant to your program are covered, validated, and run under conditions that produce reliable data.
Broad panels (300+ kinases) are valuable for early selectivity screening and safety/tox studies where you need to flag off-target liabilities across the kinome. Focused panels (30 to 150 kinases) are better suited for late-stage lead optimization when you already know your target family and need dose-response data.
Your CRO should offer both options. The ability to design a custom panel, selecting specific targets from a validated catalog, is a practical necessity for programs with defined target hypotheses. AssayQuant offers six predefined kinase panels, a wild-type phosphatase panel, and full custom panel design from more than 600 kinase and phosphatase targets.
Kinase selectivity profiling is only half the picture. Off-target phosphatase activity can drive toxicity that your kinase panel will not catch. If your compound or program involves phosphatase-adjacent biology, or if you want to identify unexpected liabilities early, ask whether your CRO partner offers phosphatase profiling using the same assay methodology.
Running kinase and phosphatase panels on the same platform, with the same kinetic readout, eliminates cross-platform variability and gives you a unified selectivity dataset.
Turnaround time is the factor that most directly affects your project's decision cadence. A two-week turnaround from compound receipt to data delivery means your team can act on selectivity results in the same project cycle. A six-week turnaround pushes your next decision into the following quarter.
Ask your prospective CRO to define turnaround precisely. Does it start from compound receipt or from when assays begin? Does it include expert review and annotation, or just raw data delivery? A stated turnaround of "two weeks" that excludes data analysis adds hidden delays to your timeline.
AssayQuant's KinSight services deliver a complete data package, including waterfall plots, kinome tree visualization, tabular percent inhibition data, annotated progress curves, and expert MOA annotation, in approximately two weeks from compound receipt.
Programs rarely move at a fixed pace. Your CRO partner should accommodate rush submissions for urgent compounds and batch scheduling for larger compound sets. Ask about scheduling cadence: does the lab run profiling on a fixed cycle (e.g., biweekly), or can ad hoc submissions be accommodated?
Knowing the scheduling structure up front prevents surprises when your medicinal chemistry team delivers a new compound series on a compressed timeline.
Raw percent inhibition values are a starting point, not a deliverable. The difference between a data dump and an actionable report determines how quickly your team can move from profiling results to program decisions.
If your CRO delivers only percent inhibition at one concentration, you have a rank-ordered list. You do not have mechanistic information. Progress curves show you the full reaction trajectory for every kinase in your panel, revealing whether inhibition is immediate or time-dependent, and whether the assay itself ran cleanly.
That curve-level data is the built-in quality control for every data point in your report. If you cannot see the curve, you cannot evaluate whether the number is trustworthy.
Automated data processing generates numbers. Expert annotation generates decisions. Look for a CRO whose scientists review every result and flag TDI signals, unusual kinetics, off-target liabilities with structural similarity to your primary target, and potential assay artifacts.
AssayQuant's scientific team annotates every KinSight report with MOA insights, TDI flags, and recommendations for follow-up studies. That expert layer converts data into a document your project team can act on immediately.
Kinome tree visualizations, waterfall plots, and downloadable data tables are not presentation accessories. They are the tools your team uses to communicate selectivity findings to cross-functional stakeholders, medicinal chemists, biologists, and program leaders.
Ask for sample reports before committing. The format and depth of the deliverable should match how your organization makes decisions. AssayQuant includes kinome tree visualization and annotated progress curves as standard deliverables in every profiling engagement.
Technical capability is necessary but not sufficient. Operational fit, the practical compatibility between your team's workflows and the CRO's processes, determines whether the partnership runs smoothly or generates logistical overhead that offsets the outsourcing advantage.
Clarify compound format, quantity, concentration, and solvent requirements before committing. Some CROs require large compound quantities or specific plate formats that do not match your internal sample management workflow. A partner that accepts flexible submission formats reduces your team's preparation burden.
Your CRO should assign a scientific point of contact, not just a project manager. When questions arise about assay conditions, unexpected kinetics, or follow-up study design, you need access to an enzymologist who understands the data. Generic customer support channels add latency to decisions that benefit from technical conversation.
AssayQuant assigns a scientific point of contact for every KinSight engagement, giving your team direct access to the enzymologists who run and interpret your assays. You can explore our approach before committing to a project.
Compound structures, selectivity profiles, and program strategy are confidential. Confirm that your CRO partner has formal confidentiality agreements in place before compound submission. Ask about data storage, access controls, and whether third parties are involved in any part of the workflow.
A structured evaluation process reduces vendor selection time and ensures you compare partners on the criteria that matter most to your program. Follow these steps to move from a long list to a committed partner.
Before contacting any CRO, document the specific deliverables your program requires. Are you running a broad selectivity screen, a focused dose-response panel, or a TDI characterization study? What ATP conditions are relevant? What kinases or phosphatases are mandatory targets?
A clear scope document accelerates the evaluation process and prevents scope creep once the engagement starts.
Ask each prospective CRO for their assay validation documentation, panel target lists, ATP concentration options, and sample reports. Review the assay format (binding vs. activity, endpoint vs. kinetic) and confirm it aligns with your data needs.
Before committing to a full panel, run a focused pilot with a small number of well-characterized compounds. Compare the CRO's results to your internal data or published reference values. Evaluate turnaround time, data depth, communication quality, and report format.
A pilot study is the most reliable predictor of long-term partnership performance. It costs less than a failed full engagement and reveals operational issues that documentation cannot.
When pilot results arrive, assess more than the numbers. Can you see progress curves? Are TDI signals flagged? Is the annotation useful for your next decision? Does the report format match how your team communicates findings internally?
Once you have identified a partner whose data quality, turnaround, and operational fit meet your requirements, negotiate terms that accommodate your program's pace. Discuss batch scheduling, rush timelines, custom panel design, and long-term pricing for repeat engagements.
Not every CRO that lists kinase profiling as a service has the depth to support your program. Watch for these warning signs during evaluation.
If a CRO delivers only summary tables without underlying kinetic data, you cannot verify the quality of individual data points. Progress curves are the quality control mechanism for every measurement. Demand access to curve-level data as a standard deliverable.
A partner that runs all assays at a single, low ATP concentration (e.g., 10 µM) limits your ability to interpret potency in a physiologically relevant context. ATP flexibility is not a premium feature. It is a prerequisite for reliable compound characterization.
If your primary contact is a sales representative rather than a scientist, your questions about assay conditions, unexpected results, or study design will be filtered through a non-technical intermediary. Direct scientific access is essential for programs where data interpretation drives the next experiment.
The timeline impact of outsourcing profiling extends beyond the turnaround for a single study. A reliable CRO partner compresses your entire decision cycle by eliminating the lag between compound synthesis and selectivity data.
When your CRO delivers annotated kinetic data in two weeks, your medicinal chemistry team can incorporate selectivity findings into the next design cycle immediately. That cadence compounds over multiple rounds of optimization, potentially compressing your lead optimization phase by months.
Off-target kinase inhibition is a well-documented source of toxicity-related clinical trial failures. Broad-panel profiling with TDI detection at physiologically relevant ATP conditions identifies these liabilities before they reach cell-based or animal studies. That early flag prevents costly late-stage attrition.
AssayQuant's KinSight profiling is increasingly used for exactly this purpose, running compounds against the roughly 400-kinase wild-type panel at 1 mM ATP to capture a physiologically relevant view of off-target activity before compounds advance to in-house assay follow-up or preclinical studies.
Selecting a profiling partner is a scientific and operational decision that directly shapes your drug discovery timeline. The criteria that matter most are assay technology (activity-based, kinetic, and run at relevant ATP conditions), data depth (progress curves with expert annotation), turnaround speed, and practical operational fit.
Use the step-by-step framework in this guide to evaluate prospective partners systematically. Run a pilot before committing. And prioritize partners who give you direct access to the scientists behind your data.
At AssayQuant, we stand with you on the frontier of drug discovery and target biology. Schedule a meeting with our scientific team to discuss your profiling needs and explore how KinSight services can support your program.
Outsourced compound profiling is the practice of sending your compounds to a specialized CRO that runs selectivity, potency, and mechanism-of-action studies on your behalf. This approach gives you access to validated kinase and phosphatase panels without building in-house capabilities.
Assay format determines what your data reveals. Activity-based kinetic assays generate progress curves that capture TDI, MOA, and true initial rates. Single-point binding or endpoint formats produce a single number that may miss critical mechanistic information about your compounds.
ATP concentration directly affects measured inhibitor potency. Running at 10 µM ATP systematically overestimates potency for ATP-competitive compounds. AssayQuant's KinSight services offer every target at ATP Km, 1 mM ATP, or a custom concentration, so you can generate potency data under conditions that reflect actual cellular physiology.
Turnaround varies by CRO. Some deliver raw data in four to six weeks. AssayQuant's KinSight services deliver a complete, expert-annotated data package in approximately two weeks from compound receipt, including progress curves, kinome tree visualization, and MOA annotation.
Ask about assay format (binding vs. activity), kinetic data depth (endpoint vs. progress curve), ATP concentration options, panel customization, turnaround definition, compound submission requirements, and whether you will have direct access to the scientists who run your assays.
Yes, if the CRO offers phosphatase panels. AssayQuant's KinSight services include phosphatase selectivity profiling using the same real-time kinetic assay approach as kinase profiling. Running both on the same platform eliminates cross-platform variability in your selectivity dataset.
Request a pilot study with well-characterized reference compounds. Compare the CRO's results to published values or your internal data. Review progress curves for linearity and quality. A partner whose data matches reference benchmarks and whose reports include expert annotation earns confidence through demonstrated performance.